Nilyph: Full Drug Profile

Nilyph - General Information

Nilyph is a derivative of theophylline which shares bronchodilator properties. Nilyph is used in asthma, chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy. Long-term enprofylline administration may be associated with elevation in liver enzyme levels and unpredictable blood levels.

Pharmacology of Nilyph

Nilyph is a synthetic dimethylxanthine derivative structurally related to theophylline and caffeine. It antagonizes erythrocyte phosphodiesterase, increasing cAMP activity.

Additional information about Nilyph

Nilyph Indication

Used in the management of symptoms of asthma. Also used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.

Mechanism Of Action

Nilyph inhibits erythrocyte phosphodiesterase, resulting in an increase in erythrocyte cAMP activity. Subsequently, the erythrocyte membrane becomes more resistant to deformity. Along with erythrocyte activity, enprofylline also decreases blood viscosity by reducing plasma fibrinogen concentrations and increasing fibrinolytic activity.

Generic Name

Enprofylline

Synonyms

3-n-Propylxanthine; 3-Propylxanthine; Enprofilina [INN-Spanish]; Enprofyllinum [INN-Latin]

Drug Category

Anti-Asthmatic Agents; Antiarrhythmic Agents; Bronchodilator Agents; Anti-Inflammatory Agents, Non-Steroidal

Drug Type

Small Molecule; Approved

Other Brand Names containing Enprofylline

Nilyph; Oxeze;

Absorption

Rapidly absorbed from the digestive tract

Protein Binding

49%

Half Life

1.9 hours

Chemical IUPAC Name

3-propyl-7H-purine-2,6-dione

Chemical Formula

C8H10N4O2

Organisms Affected

Humans and other mammals